secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2024-01-04T23:59:59+00:00
Accession:  0001193125-24-002438
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia Therapeutics provides strategic update, cash ~$1.0B, workforce reduction of ~15%
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities ~$1.0B as of Dec 31, 2023; expected to fund operations into mid-2026.
- Workforce reduction of approximately 15% and pause of select exploratory research-stage programs to focus on key priorities.
- Initiated pivotal Phase 3 MAGNITUDE trial of NTLA-2001 for ATTR amyloidosis with cardiomyopathy; first patient dosing expected Q1 2024.
- Completed enrollment and dosing in Phase 2 portion of NTLA-2002 study for hereditary angioedema; Phase 3 initiation planned 2H 2024.
- Board member John Crowley departed in December following his appointment as CEO of BIO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312524002438/0001193125-24-002438-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312524002438/d655921d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-002438

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer